N. Patel
Northwestern University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by N. Patel.
British Journal of Dermatology | 2017
Rishi Chopra; Paras P. Vakharia; Ryan Sacotte; N. Patel; Supriya Immaneni; T. White; Robert Kantor; Derek Y. Hsu; Jonathan I. Silverberg
Scoring systems for assessing the signs of atopic dermatitis (AD) are complex and difficult to interpret. Severity strata are helpful to interpret these assessments properly.
Annals of Allergy Asthma & Immunology | 2017
Paras P. Vakharia; Rishi Chopra; Ryan Sacotte; K.R. Patel; V. Singam; N. Patel; Supriya Immaneni; T. White; Robert Kantor; Derek Y. Hsu; Jonathan I. Silverberg
BACKGROUND Atopic dermatitis (AD) is associated with itch, skin inflammation and barrier disruption, and scratching, all of which may be associated with skin pain. OBJECTIVE To characterize the patient burden of skin pain in AD. METHODS We performed a prospective dermatology practice-based study using questionnaires and evaluation by a dermatologist. RESULTS Overall, 305 patients (age range, 13-97 years) were included in the study, with 564 encounters. The cohort included 195 females (63.9%) and 193 whites (63.7%). The mean (SD) age at enrollment was 42.3 (18.1) years, and the mean (SD) age of patient-reported AD onset was 29.6 (31.9) years. At baseline, 144 patients (42.7%) reported skin pain in the past week, with 42 (13.8%) reporting severe or very severe pain. Twenty-four (16.8%) thought the skin pain was part of their itch, 16 (11.2%) from scratching, and 77 (72.0%) from both. Patients with skin pain were more likely to describe their itch using terms that resembled neuropathic pain. Prevalence of skin pain was increased in patients with vs without excoriations (72.6% vs 57.6%; χ2 test P = .02) but not other morphologic characteristics. Skin pain severity was most strongly correlated with the Patient-Oriented Eczema Measure (Spearman ρ = 0.54), followed by ItchyQOL (ρ = 0.52), 5-dimensions of itch scale (ρ = 0.47), Dermatology Life Quality Index (ρ = 0.45), numeric rating scale for itch (ρ = 0.43) and sleep (ρ = 0.36), Patient Health Questionnaire 9 (ρ = 0.36), patient-reported global AD severity (ρ = 0.34), Eczema Area and Severity Index (ρ = 0.23), and objective Scoring AD index (ρ = 0.20) (P < .001 for all). Patients with both severe itch and pain vs those with only one or neither symptom being severe had significant increases in all these measures. CONCLUSION Skin pain is a common and burdensome symptom in AD. Skin pain severity should be assessed with itch severity in AD patients and may be an important end point for monitoring treatment response.
Allergy | 2018
Paras P. Vakharia; Rishi Chopra; Ryan Sacotte; N. Patel; Supriya Immaneni; T. White; Robert Kantor; Derek Y. Hsu; Jonathan I. Silverberg
Atopic dermatitis (AD) is associated with a heterogeneous presentation and clinical course. There is a lack of simple and validated severity assessments that are feasible for clinical practice and epidemiological research.
British Journal of Dermatology | 2018
Paras P. Vakharia; Rishi Chopra; Ryan Sacotte; N. Patel; Supriya Immaneni; T. White; Robert Kantor; Derek Y. Hsu; Eric L. Simpson; Jonathan I. Silverberg
Several patient‐reported outcomes have been used to assess the burden of atopic dermatitis (AD). Some are disease specific, such as the Patient‐Oriented Eczema Measure (POEM), while others pertain to itch, for example the numerical rating scale (NRS)‐itch, ItchyQoL and 5‐D itch, or dermatological disease in general, for example the Dermatology Life Quality Index (DLQI). Development of severity strata is essential for proper interpretability of these assessments.
The Journal of Allergy and Clinical Immunology | 2017
Rishi Chopra; Paras P. Vakharia; Ryan Sacotte; N. Patel; Supriya Immaneni; T. White; Robert Kantor; Derek Y. Hsu; Jonathan I. Silverberg
Capsule Summary The present study shows a complex relationship between EASI and SCORAD. The results provide support for inclusion of objective-SCORAD and/or SCORAD in addition to EASI in clinical trials.
British Journal of Dermatology | 2018
K.R. Patel; V. Singam; Paras P. Vakharia; Rishi Chopra; Ryan Sacotte; N. Patel; Supriya Immaneni; Robert Kantor; Derek Y. Hsu; Jonathan I. Silverberg
Standardized quality‐of‐life (QoL) assessments can provide important and clinically relevant information. There is currently a lack of standardization in QoL assessments used in atopic dermatitis (AD).
The Journal of Allergy and Clinical Immunology: In Practice | 2017
Jonathan I. Silverberg; Paras P. Vakharia; Rishi Chopra; Ryan Sacotte; N. Patel; Supriya Immaneni; Takeisha White; Robert Kantor; Derek Y. Hsu
The Journal of Allergy and Clinical Immunology | 2018
Niharika Rath; Charles S. Barnes; Brian Lee; N. Patel
Journal of Investigative Dermatology | 2018
K.R. Patel; V. Singam; Paras P. Vakharia; Rishi Chopra; Ryan Sacotte; S. Rastogi; H. Lee; N. Patel; Supriya Immaneni; Robert Kantor; Derek Y. Hsu; Jonathan I. Silverberg
Journal of Investigative Dermatology | 2017
Ryan Sacotte; Paras P. Vakharia; Rishi Chopra; N. Patel; Supriya Immaneni; T. White; Robert Kantor; Derek Y. Hsu; Eric L. Simpson; Jonathan I. Silverberg